Biogen Idec has filed a biologics license application with the FDA for approval to use recombinant factor VIII Fc fusion protein as a treatment for hemophilia A. The drug belongs to a new class of long-lasting clotting factor treatments. The application was based on positive results of the late-stage A-LONG trial.
Biogen submits hemophilia A drug for FDA approval
SmartBrief Job Listings for Health Care
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.
|Assistant Vice President - Dental Director||